Neumirna Therapeutics
@neumirna.com
Developing miRNA-based therapies targeting root causes of neurological diseases like epilepsy and Parkinson's. Transforming outcomes beyond symptom management.
Neumirna Therapeutics's Company Logos
Neumirna Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#28769D
Jelly Bean
40, 118, 157
200, 59, 39
75, 25, 0, 38
#ADCCFB
Sail
173, 204, 251
216, 91, 83
31, 19, 0, 2
#0A5952
Deep Sea Green
10, 89, 82
175, 80, 19
89, 0, 8, 65
About Neumirna Therapeutics
NEUmiRNA Therapeutics is a Danish pharmaceutical start-up based in Copenhagen. Founded in 2020, NEUmiRNA aims to revolutionize the treatment of neurological conditions through innovative disease modification strategies. Led by a team of renowned experts in the field of neuroscience, NEUmiRNA is focused on developing groundbreaking therapies that address the underlying causes of these conditions.
The company's founders, Dr. Henrik Klitgaard and Prof. Sakari Kauppinen, bring with them a wealth of experience and expertise. Dr. Klitgaard, as the former VP for Neuroscience at UCB, played a pivotal role in the discovery of the synaptic vesicle 2A mechanism for epilepsy and the development of two groundbreaking antiepileptic drugs - Keppra and Briviact. Prof. Kauppinen, on the other hand, led the miRNA Research & Drug Discovery team at Santaris Pharma, where he oversaw the development of Miravirsen, the world's first microRNA-targeted drug.
Supported by a dedicated team of scientists and researchers, NEUmiRNA is committed to advancing the understanding and treatment of neurological conditions. With collaborations with esteemed institutions like the Centre for RNA Medicine, NEUmiRNA is at the forefront of cutting-edge research and innovation.
Investors have recognized the immense potential of NEUmiRNA, with collaborations and funding from institutions like the Novo Nordisk Foundation. Through their groundbreaking work, NEUmiRNA is paving the way for a brighter future for individuals suffering from neurological conditions.
